original ) (raw )Antral Follicles Count and Anti-Müllerian Hormone Levels after Gonadotoxic Chemotherapy in Patients with Breast Cancer: Cohort Study
Helena Corleta
Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia, 2017
View PDFchevron_right
Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer
Mikkel Rosendahl , Tom Kelsey
View PDFchevron_right
Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women
Piero Fregatti
Breast Cancer: Targets and Therapy, 2021
View PDFchevron_right
Prediction of Postmenopausal Status in Premenopausal Early Stage Breast Cancer Patients after Adjuvant Chemotherapy
Osama Elzaafarany
Hematology & Transfusion International Journal
View PDFchevron_right
Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer
Kathryn Ruddy
Fertility and Sterility, 2010
View PDFchevron_right
Hormone Therapy and Factors Affecting Fertility of Women Under 50-Year-Old with Breast Cancer
behnaz marzbani
Breast Cancer: Targets and Therapy, 2019
View PDFchevron_right
Impact of breast cancer treatment on fertility
Olivia Pagani
tara.tcd.ie
View PDFchevron_right
Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age
Anders Juul
Fertility and Sterility, 2010
View PDFchevron_right
Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy
Yasmin Gosiengfiao , Maureen Prewitt
Fertility and Sterility, 2013
View PDFchevron_right
Fertility and adjuvant treatment in young women with breast cancer
Kathryn Ruddy
The Breast, 2007
View PDFchevron_right
Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive antimüllerian hormone assay
Didier Dewailly
Fertility and Sterility, 2014
View PDFchevron_right
Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients
Piero Fregatti
Journal of the National Cancer Institute, 2021
View PDFchevron_right
Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments
Teresa Almeida Santos
Journal of Ovarian Research
View PDFchevron_right
Influence of chemotherapy to hormonal levels in postmenopausal breast cancer patients
L. Petruzelka
Neoplasma, 2008
View PDFchevron_right
Fertility and menopausal outcomes in young breast cancer survivors
Ebonie Sampson
Clinical breast …, 2008
View PDFchevron_right
The PREgnancy and FERtility (PREFER) Study Investigating the Need for Ovarian Function and/or Fertility Preservation Strategies in Premenopausal Women With Early Breast Cancer
Piero Fregatti
Frontiers in Oncology, 2021
View PDFchevron_right
Fertility after breast cancer treatment
Rebecca Johnson
European Journal of Obstetrics & Gynecology and Reproductive Biology, 2014
View PDFchevron_right
Ovarian Reserve after Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis
Ilaria Romito
Journal of Personalized Medicine, 2021
View PDFchevron_right
Anti-Müllerian Hormone and Antral Follicle Count Reveal a Late Impair- Ment of Ovarian Reserve in Patients Undergone Low Gonadotoxic Regimens for Haematological Malignancies
Alessio Perandini
2013
View PDFchevron_right
AMH as an ovarian function predictor in premenopausal female breast cancer patients receiving chemotherapy is effective only for those over 35 years old
sixuan Liu
2020
View PDFchevron_right
FERTILITY AND BREAST CANCER
Kheira REKAI , IJCIRAS Research Publication
IJCIRAS, 2020
View PDFchevron_right
Anti-mullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies
Frank Jong
Human Reproduction, 2008
View PDFchevron_right
Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology
Ivan Moschetti
European journal of cancer (Oxford, England : 1990), 2017
View PDFchevron_right
Patients with cancer at the margins of reproductive age had reduced levels of anti‐Müllerian hormone compared with patients experiencing infertility
srwa khalid
International Journal of Gynecology & Obstetrics, 2016
View PDFchevron_right
Adjuvant therapy with GnRH agonists/tamoxifen in breast cancer could be a good council for patients with hormone receptor-positive tumors and wish to preserve fertility
Jose Franco Junior
JBRA Assisted Reproduction
View PDFchevron_right
Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?
Cynthia Villarreal-Garza
Clinical Medicine Insights: Reproductive Health
View PDFchevron_right
Predicting chemotherapy‐induced menopause using baseline and post‐chemotherapy anti‐Müllerian hormone levels: Results of a pilot study
AMITESH Roy
Cancer Reports, 2021
View PDFchevron_right
Acute onset of ovarian dysfunction in young females after start of cancer treatment
Ingrid Øra
Pediatric Blood & Cancer, 2013
View PDFchevron_right
Impact of cancer therapies on ovarian reserve
Jill Ginsberg
Fertility and Sterility, 2012
View PDFchevron_right
Predictors of ovarian reserve in young women with breast cancer
Ashlesha Patel
British Journal of Cancer, 2007
View PDFchevron_right
Amenorrhea, fertility preservation, and counseling among young women treated with anthracyclines and taxanes for early-stage breast cancer, a retrospective study
omar shahin
Medicine, 2020
View PDFchevron_right
Anti-Müllerian Hormone and Antral Follicle Count Reveal a Late Impairment of Ovarian Reserve in Patients Undergoing Low-Gonadotoxic Regimens for Hematological Malignancies
Alessio Perandini
Oncologist, 2013
View PDFchevron_right